Combining bevacizumab with erlotinib shrinks tumors in patients with aggressive, HLRCC-associated kidney cancers.
All tagged cancer
Combining bevacizumab with erlotinib shrinks tumors in patients with aggressive, HLRCC-associated kidney cancers.
Researchers have learned how neurons in the brain can be damaged by the chemotherapy drug Ara-C.
A novel therapy helps eliminate recurring respiratory growths in patients — and the frequent surgeries they required.
Full story at National Cancer Institute
A personalized approach to cellular immunotherapy helps shrink solid tumors.
Cancer-killing natural killer cells could pave the way to off-the-shelf immunotherapy for solid tumors.
Adding a T-cell receptor to CAR T cells may reduce side effects of immunotherapies designed to target solid tumors.
U of U Health scientists open the door to clinical advances by examining the ways disease impacts the body, molecule by molecule.
Aberrant RAS proteins, found in 20 to 30 percent of cancers, can promote the export of proteins from a cell’s nucleus to its cytoplasm, where some can contribute to cancerous growth.
Waves of regulatory changes can transform self-renewing neuroblastoma cells into neurons.